Clinical trial imaging services are important in the healthcare sector because they use advanced imaging techniques to support and improve clinical trials. These techniques are critical for testing new drugs and treatments before they are offered to patients. Imaging services encompass methods such as MRI, CT scan and PET scan. These are critical to guarantee the safety and efficacy of new treatments.
The industry has been growing steadily because of the rising number of clinical trials and the need for precise data. More pharmaceutical and biotechnology companies are recognizing the importance of imaging in their research. In addition, stricter regulations are boosting the demand for high-quality imaging services. This develops an opportunity for healthcare companies to bring new inventions and improve their services. As a result, the clinical trial imaging services contribute greatly to medical research development and improve patient outcomes.
According to a recent report published by Allied Market Research, the global clinical trial imaging services market is predicted to exhibit a stunning CAGR of 5.6% from 2020 to 2027.
The growing role of imaging in neuroscience trials
Over the years, the use of imaging in neuroscience clinical trials has grown considerably. Imaging techniques such as MRI and PET help researchers monitor brain structure and function in real time. This method is very important for diagnosing neurological problems, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
For example, in Alzheimer’s research, MRI scans help track changes in brain size and shape over time. This permits scientists to figure out the progression of disease. It is also testing the efficacy of new treatments. Similarly, PET scans can detect amyloid plaques associated with Alzheimer's disease. They offer useful facts about drugs that help reduce the buildup of harmful deposits.
In addition, imaging helps identify biomarkers, which are measurable indicators of a biological condition. Early detection of these markers in clinical trials allows researchers to predict how patients will respond to treatments. The growth of imaging technology improves the efficiency and effectiveness of clinical trials, which eventually results in better treatments for brain-related disorders. With the continued evolution of technologies, the incorporation of imaging in neurology is likely to become very important for shaping the future of medical research.
AI innovations in enhancing precision in clinical trial imaging
Automation is changing clinical trial imaging workflow. It offers notable improvements in compliance, data quality, accuracy, and decision-making. Three practical AI applications in this domain include PHI identification and removal, image quality control, and reviewer assessments. Regulations regarding privacy, such as HIPAA and GDPR, require that personal health information be removed from medical image files before sharing them. In the past, this process has been done manually and was error prone. However, Medidata’s ByePHI AI algorithm, launched in 2021, simplifies the process by automatically detecting and removing PHI from DICOM tags and pixel data, ensuring compliance and reducing human error.
In addition, image quality control, a time-consuming and subjective task, is being improved by AI algorithms that detect important parameters such as anatomical coverage and contrast enhancement. This automation minimizes subjectivity and accelerates the process, resulting in better data for clinical endpoints.
On the other hand, reviewer assessments in oncology trials, which can incur high costs and depict variability, are being streamlined using AI-assisted lesion measurement. Medidata and Dassault Systèmes’ AI algorithms automate the processes of lesion identification and classification. It allows the radiologists to review and make any necessary adjustments. This approach saves time and reduces expenses, as well as decreasing variability among reviewers, guaranteeing consistent outcomes. Therefore, these advances enhance the collection, processing, and analysis of imaging data in clinical trials.
Calyx Invicro and BAMF Health collaborate to revolutionize clinical trial imaging
In June 2024, Calyx / Invicro, a well-known company specializing in medical imaging tools for clinical research, announced a strategic alliance with BAMF Health, a leading expert in molecular imaging and theranostics. This collaboration aims to improve the practical applications of radioligand therapies and immuno-oncology agents. It tackles the problems in the current service system. This often results in duplication of effort and extended development timelines.
The combination of BAMF's Health advanced radio-pharmacy and Calyx/ Invicro's expertise for managing a wide range of alpha, beta, and gamma agents in radiochemistry allows pharmaceutical companies to fully resource the translation of clinical trials. A major project in this collaboration involves actinium-225, with TerraPower supplying the material and BAMF utilizing its GE HealthCare StarGuide™ SPECT/CT technology to improve the study and application.
Edward Hogan, the Chief Operating Officer of Calyx / Invicro, emphasized the success of their translational model in CNS research. He also showed confidence that this partnership is expected to drive similar innovations in oncology. Dan Rogers, the director of clinical trials at BAMF Health, mentioned that collaboration is predicted to help overcome unique demanding situations in the improvement of modern therapies. This effort aims to make precision medicine more available to patients.
Wrapping up
Clinical trial imaging services are necessary for evaluating new treatments to make sure they are safe and effective. With recent technological advancements, such as artificial intelligence and advanced imaging techniques, researchers are able to enhance data accuracy and make processes more efficient. These advancements significantly help medical research, especially in neuroscience, resulting in better patient outcomes and more effective treatments.
✍ **𝑨𝒓𝒕𝒊𝒄𝒍𝒆 𝒘𝒓𝒊𝒕𝒆𝒓: Harshada Dive
Author’s Bio: - Harshada Dive is a computer engineer who loves experimenting with trending topics and is passionate about presenting contemporary trends creatively to her audience. Her writing skillfully integrates knowledge and creativity, reflecting her dedication to creating engaging and thoughtful content. Outside of her professional pursuits, Harshada enjoys gardening and listening to inspirational podcasts.
0 Comments